Dexcom (DXCM) Return on Capital Employed (2011 - 2026)

Dexcom (DXCM) has 16 years of Return on Capital Employed data on file, last reported at 24.24% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 658.0% year-over-year to 24.24% in Q1 2026; TTM through Mar 2026 was 24.24%, a 658.0% increase from a year earlier, with the FY2025 full-year figure at 21.36%, up 393.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 24.24%, up from 19.09% in the prior quarter.
• Over the last five years, Return on Capital Employed for DXCM reached as high as 24.24% in Q1 2026 and fell as low as 5.48% in Q2 2022.
• Historically, Return on Capital Employed has averaged 13.55% across 5 years, with a median of 12.97% in 2024.
• Across the five-year window, Return on Capital Employed tumbled 349 bps in 2022 and jumped 658 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 11.83% in 2022, then increased by 4 bps to 12.26% in 2023, then soared by 40 bps to 17.21% in 2024, then increased by 11 bps to 19.09% in 2025, then climbed by 27 bps to 24.24% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 24.24% in Q1 2026, 19.09% in Q4 2025, and 19.07% in Q3 2025.